Pharmacokinetics of linagliptin in subjects with hepatic impairment

AIM: To investigate whether hepatic impairment affects linagliptin pharmacokinetics, pharmacodynamics and tolerability. METHOD: This open label, parallel group, single centre study enrolled patients with mild (n = 8), moderate (n = 9) or severe (n = 8) hepatic impairment and healthy subjects (n = 8)...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Graefe-Mody, Ulrike, Rose, Peter, Retlich, Silke, Ring, Arne, Waldhauser, Lisa, Cinca, Rodica, Woerle, Hans-Juergen
Format: Artigo
Idioma:Inglês
Publicat: Blackwell Science Inc 2012
Matèries:
Pharmacokinetics
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3394131/
https://ncbi.nlm.nih.gov/pubmed/22242621
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2012.04173.x
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars